T3 Companies’s Japer Therapeutics Warrants JSPRW Stock Holding History

T3 Companies’s Portfolio JSPRW Stock Details JSPRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,200	Closed	-$569	–	200
2025 Q4	$569	Buy	+14,200	New	+$1.6K	﹤0.01%	194

Other funds holding JSPRW

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

TCM

Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

T3 Companies's JSPRW Position: Q1 2026 in Review

T3 Companies sold out of Japer Therapeutics Warrants (JSPRW) in Q1 2026, closing a stake of 14,200 shares — an estimated $569 sold.

T3 Companies first reported a position in JSPRW in Q4 2025 and held it in 1 quarter. The position peaked at $569 in Q4 2025. 7 funds tracked by Wall St. Rank hold JSPRW as of Q1 2026.

T3 Companies reported no remaining Japer Therapeutics Warrants position as of Q1 2026 after selling out during the quarter.
T3 Companies sold 14,200 Japer Therapeutics Warrants shares in Q1 2026, an estimated $569.
T3 Companies first reported a position in Japer Therapeutics Warrants in Q4 2025 and held it in 1 quarter.
T3 Companies's Japer Therapeutics Warrants position peaked at $569 in Q4 2025.
7 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q1 2026.

Based on T3 Companies's 13F filing for Q1 2026, filed 7 May 2026.